BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23(2): 336-344 [PMID: 28127207 DOI: 10.3748/wjg.v23.i2.336]
URL: https://www.wjgnet.com/1007-9327/full/v23/i2/336.htm
Number Citing Articles
1
Jordan Shapiro, Jessica Bernica, Ruben Hernaez. Risk of Bias Analysis of Systematic Reviews of Probiotics for Treatment of Irritable Bowel SyndromeClinical Gastroenterology and Hepatology 2019; 17(4): 784 doi: 10.1016/j.cgh.2018.07.010
2
Maura Di Vito, Maria Grazia Bellardi, Maurizio Sanguinetti, Francesca Mondello, Antonietta Girolamo, Lorenzo Barbanti, Stefania Garzoli, Manuela Sabatino, Rino Ragno, Alberto Vitali, Ivana Palucci, Brunella Posteraro, Antonio Gasbarrini, Gian Maria Prati, Giovanni Aragona, Paola Mattarelli, Francesca Bugli. Potent In Vitro Activity of Citrus aurantium Essential Oil and Vitis vinifera Hydrolate Against Gut Yeast Isolates from Irritable Bowel Syndrome Patients—The Right Mix for Potential Therapeutic UseNutrients 2020; 12(5): 1329 doi: 10.3390/nu12051329
3
Soo Liang Ooi, Dianne Correa, Sok Cheon Pak. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome – What is the current evidence?Complementary Therapies in Medicine 2019; 43: 73 doi: 10.1016/j.ctim.2019.01.010
4
A. P. S. Hungin, C. R. Mitchell, P. Whorwell, C. Mulligan, O. Cole, L. Agréus, P. Fracasso, C. Lionis, J. Mendive, J.-M. Philippart de Foy, B. Seifert, K.-A. Wensaas, C. Winchester, N. de Wit. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensusAlimentary Pharmacology & Therapeutics 2018; 47(8): 1054 doi: 10.1111/apt.14539
5
Industrially Important Fungi for Sustainable DevelopmentFungal Biology 2021; : 393 doi: 10.1007/978-3-030-67561-5_12
6
Lynne V. McFarland, Tarkan Karakan, Ali Karatas. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysiseClinicalMedicine 2021; 41: 101154 doi: 10.1016/j.eclinm.2021.101154
7
Michael Camilleri. Management Options for Irritable Bowel SyndromeMayo Clinic Proceedings 2018; 93(12): 1858 doi: 10.1016/j.mayocp.2018.04.032
8
Thuy-Linh Nguyen, Mingzhan Toh, Yuyun Lu, Sebastian Ku, Shao-Quan Liu. Biovalorization of Market Surplus Bread for Development of Probiotic-Fermented Potential Functional BeveragesFoods 2022; 11(3): 250 doi: 10.3390/foods11030250
9
Lucinda A. Harris, Noemi Baffy. Modulation of the gut microbiota: a focus on treatments for irritable bowel syndromePostgraduate Medicine 2017; 129(8): 872 doi: 10.1080/00325481.2017.1383819
10
Florian Mourey, Amélie Decherf, Jean-François Jeanne, Mathieu Clément-Ziza, Marie-Lise Grisoni, François Machuron, Sophie Legrain-Raspaud, Arnaud Bourreille, Pierre Desreumaux. <i>Saccharomyces cerevisiae </i>I-3856 in irritable bowel syndrome with predominant constipationWorld Journal of Gastroenterology 2022; 28(22): 2509-2522 doi: 10.3748/wjg.v28.i22.2509
11
Efstathia I. Paramera, Vaios T. Karathanos, Spyros J. Konteles. Microencapsulation in the Food Industry2023; : 343 doi: 10.1016/B978-0-12-821683-5.00002-9
12
Advances in Probiotics for Sustainable Food and MedicineMicroorganisms for Sustainability 2021; 21: 181 doi: 10.1007/978-981-15-6795-7_8
13
Asim K. Duttaroy. Evidence-Based Nutrition and Clinical Evidence of Bioactive Foods in Human Health and Disease2021; : 269 doi: 10.1016/B978-0-12-822405-2.00006-2
14
UegWeek 2020 Poster PresentationsUnited European Gastroenterology Journal 2020; 8(S8): 144 doi: 10.1177/2050640620927345
15
Ao Liu, Wenkang Gao, Yixin Zhu, Xiaohua Hou, Huikuan Chu. Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel SyndromeToxins 2022; 14(9): 596 doi: 10.3390/toxins14090596
16
Natalie Ramsy, Sonia Michail. Encyclopedia of Gastroenterology2020; : 289 doi: 10.1016/B978-0-12-801238-3.66050-6
17
C. Roussel, A. Sivignon, A. de Vallée, G. Garrait, S. Denis, V. Tsilia, N. Ballet, P. Vandekerckove, T. Van de Wiele, N. Barnich, S. Blanquet-Diot. Anti-infectious properties of the probiotic Saccharomyces cerevisiae CNCM I-3856 on enterotoxigenic E. coli (ETEC) strain H10407Applied Microbiology and Biotechnology 2018; 102(14): 6175 doi: 10.1007/s00253-018-9053-y
18
Angel de la Cruz Pech-Canul, David Ortega, Antonio García-Triana, Napoleón González-Silva, Rosa Lidia Solis-Oviedo. A Brief Review of Edible Coating Materials for the Microencapsulation of ProbioticsCoatings 2020; 10(3): 197 doi: 10.3390/coatings10030197
19
Nobuo Fuke, Koichi Aizawa, Hiroyuki Suganuma, Tomohisa Takagi, Yuji Naito. Effect of combined consumption of Lactobacillus brevis KB290 and β-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trialInternational Journal of Food Sciences and Nutrition 2017; 68(8): 973 doi: 10.1080/09637486.2017.1311843
20
Caroline Valibouze, Silvia Speca, Caroline Dubuquoy, Florian Mourey, Lena M'Ba, Lucil Schneider, Marie Titecat, Benoît Foligné, Michaël Genin, Christel Neut, Philippe Zerbib, Pierre Desreumaux. <i>Saccharomyces cerevisiae</i> prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic ratsWorld Journal of Gastroenterology 2023; 29(5): 851-866 doi: 10.3748/wjg.v29.i5.851
21
Adelina Nicoleta Galica, Reitano Galica, Dan Lucian Dumitrașcu. Diet, fibers, and probiotics for irritable bowel syndromeJournal of Medicine and Life 2022; 15(2): 174 doi: 10.25122/jml-2022-0028
22
E. Gabrielli, E. Pericolini, N. Ballet, E. Roselletti, S. Sabbatini, P. Mosci, A. Cayzeele Decherf, F. Pélerin, S. Perito, P. Jüsten, A. Vecchiarelli. Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasisBeneficial Microbes 2018; 9(2): 219 doi: 10.3920/BM2017.0099
23
Ravichandran Gayathri, Thangavelu Aruna, Sivaraman Malar, Bennur Shilpa, Karukkupalayam Ramasamy Dhanasekar. Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndromeInternational Journal of Colorectal Disease 2020; 35(1): 139 doi: 10.1007/s00384-019-03462-4
24
Charles C. Herndon, Yen‐Po Wang, Ching‐Liang Lu. Targeting the gut microbiota for the treatment of irritable bowel syndromeThe Kaohsiung Journal of Medical Sciences 2020; 36(3): 160 doi: 10.1002/kjm2.12154
25
Legaki Evangelia, Eleni Anna Karanasou, Maria Gazouli. Gut Microbiome-Related Diseases and TherapiesThe Microbiomes of Humans, Animals, Plants, and the Environment 2021; 1: 41 doi: 10.1007/978-3-030-59642-2_3
26
Olivia Mondal, Devanshi Khanna, Shalja Panwar, Shilpa Negi, Sneha Basu. Systematic Review on Therapeutic Applications of Yeast 'Saccharomyces'International Journal of Scientific Research in Science and Technology 2021; : 174 doi: 10.32628/IJSRST218226
27
Moghaddaseh Jahanshahi, Parisa Maleki Dana, Bita Badehnoosh, Zatollah Asemi, Jamal Hallajzadeh, Mohammad Ali Mansournia, Bahman Yousefi, Bahram Moazzami, Shahla Chaichian. Anti-tumor activities of probiotics in cervical cancerJournal of Ovarian Research 2020; 13(1) doi: 10.1186/s13048-020-00668-x
28
Bruno K. Rodiño-Janeiro, María Vicario, Carmen Alonso-Cotoner, Roberto Pascua-García, Javier Santos. A Review of Microbiota and Irritable Bowel Syndrome: Future in TherapiesAdvances in Therapy 2018; 35(3): 289 doi: 10.1007/s12325-018-0673-5
29
Kajal Farahmandi, Sadegh Sulaimany. Advances in Probiotics for Health and Nutrition [Working Title]2023;  doi: 10.5772/intechopen.109717
30
Eirini Dimidi, Megan Rossi, Kevin Whelan. Irritable bowel syndrome and dietCurrent Opinion in Clinical Nutrition & Metabolic Care 2017; 20(6): 456 doi: 10.1097/MCO.0000000000000416
31
Yuying Liu, Dat Q. Tran, J. Marc Rhoads. Probiotics in Disease Prevention and TreatmentThe Journal of Clinical Pharmacology 2018; 58: S164 doi: 10.1002/jcph.1121
32
Roberta Gaziano, Samuele Sabbatini, Elena Roselletti, Stefano Perito, Claudia Monari. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal InfectionsFrontiers in Microbiology 2020; 11 doi: 10.3389/fmicb.2020.00718
33
Rajnish Prakash Singh, Afreen Shadan, Ying Ma. Biotechnological Applications of Probiotics: A Multifarious Weapon to Disease and Metabolic AbnormalityProbiotics and Antimicrobial Proteins 2022; 14(6): 1184 doi: 10.1007/s12602-022-09992-8
34
P. Layer, V. Andresen, H. Allescher, S. C. Bischoff, M. Claßen, S. Elsenbruch, M. Freitag, T. Frieling, M. Gebhard, M. Goebel-Stengel, W. Häuser, G. Holtmann, J. Keller, M. E. Kreis, W. Kruis, J. Langhorst, P. Lynen Jansen, A. Madisch, H. Mönnikes, S. Müller-Lissner, B. Niesler, C. Pehl, D. Pohl, M. Raithel, G. Röhrig-Herzog, M. Schemann, S. Schmiedel, J. Schwille-Kiuntke, M. Storr, J. C. Preiß, T. Andus, S. Buderus, U. Ehlert, M. Engel, A. Enninger, W. Fischbach, A. Gillessen, J. Gschossmann, F. Gundling, S. Haag, U. Helwig, S. Hollerbach, M. Karaus, M. Katschinski, H. Krammer, R. Kuhlbusch-Zicklam, H. Matthes, D. Menge, S. Miehlke, M. C. Posovszky, R. Schaefert, A. Schmidt-Choudhury, O. Schwandner, A. Schweinlin, H. Seidl, A. Stengel, J. Tesarz, I. van der Voort, W. Voderholzer, G. von Boyen, J. von Schönfeld, T. Wedel. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016Zeitschrift für Gastroenterologie 2021; 59(12): 1323 doi: 10.1055/a-1591-4794
35
Amelie Decherf, Elodie Dehay, Mickaël Boyer, Mathieu Clément-Ziza, Bertrand Rodriguez, Sophie Legrain-Raspaud. Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral AdministrationNutrients 2020; 12(8): 2211 doi: 10.3390/nu12082211
36
Pablo Roman, Raquel Abalo, Eva M. Marco, Diana Cardona. Probiotics in digestive, emotional, and pain-related disordersBehavioural Pharmacology 2018; 29(2 and 3): 103 doi: 10.1097/FBP.0000000000000385